Bruk av livskvalitetsbegrepet i medisinsk forskning -til gagn eller ugagn?

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 27, 1998, Pages 4247-4251

  Wyller, Torgeir Bruun ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CONCEPT FORMATION; EVALUATION; HUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESEARCH; REVIEW;

CONCEPT FORMATION; EVALUATION STUDIES; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RESEARCH;

EID: 0032505920     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Idler EL, Kasl SV, Lemke JH. Self-evaluated health and mortality among the elderly in New Haven, Connecticut, and Iowa and Washington counties, Iowa, 1982-1986. Am J Epidemiol 1990: 131: 91 -103.
2. de Lateur BJ. Quality of life: a patient-centred outcome. Arch Phys Med Rehabil 1997; 78: 237-9.
3. von der Lieth L. Mental health problems and other rehabilitation matters for adult deaf and hard of hearing people. K0benhavn: European Society for Mental Health and Deafness, 1996.
4. Hagen J. Faerre innleggelser - bedre livskvalitet. Legemidler og samfunn 1997; 18, nr. 9-10: 32-3.
5. Larsen RL. Unders0kelser viser: Forverrct livskvalitet i Oslo-bydel etter Romeriksporten. Aftenposten (morgenutgave) 12.12.1997.
6. Hunt SM. The problem of quality of life. Qual Life Res 1997; 6: 205-12.
7. Heap KK. Vurdering av réhabilite og validitet ved kvalitativc data. Tidsskr Nor Laegeforen 1988; 108: 3191-5.
8. Elster J. Metoder og prinsipper i hermeneutisk forskningstradisjon. Nord Psykiatr Tidsskr 1979; 33: 135-49.
9. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the Index of Well-being. Health Serv Res 1976; 11: 478-507.
10. Ware JE, Oandek B. The SF-36 health survey: development and use in mental health research and the IQOLA project. Int J Ment Health 1994;23:49-73.
11. Anderson C, Laubscher S, Burns R. Validation of the Short Form 36 (SF-36) health survey questionnaire among stroke patients. Stroke 1996; 27: 1812-6.
12. de Haan R, Aaronsen N, Limburg M, Hewer RL, van Crewel H. Measuring quality of life in stroke. Stroke 1993; 24: 320-7.
13. Mastekaasa A. Mâling av opplevd livskvalitet. I: KleivenJ, red. Etforskningsprogramblirtil. Rapport fra det forste programseminaret om milj0betinget livskvalitet. Oslo: Norges forskningsrâd, 1998: 53-75.
14. Diener E. Subjective well-being. Psychol Bull 1984; 95: 542-75.
15. Myers DG, Diener E. Who is happy? Psychol Sei 1995; 6: 109.
16. Mastekaasa A, Mourn T, Nasss S, Sorensen T. Livskvalitetsforskning. ISF rapport 88: 6. Oslo: Institut for samfunnsforskning, 1988.
17. Pavot W, Diener E. Review of the satisfaction with life scale. Psychol Assessment 1993; 5: 164-72.
18. Holmen J, Midthjell K, Bjartveit K, Hjort PF, Lund-Larsen PG, Mourn T et al. The Nord-Trandelag Health Survey 1984-86. Purpose, background and methods. Participation, non-participation and frequency distributions. Verdal: Statens institutt for folkehelse, 1990.
19. Testa MA. Simonson DC. Assessment of quality-of-life outcomes. N Engl J Mcd 1996; 334: 835-40.
20. Aaronsen NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
21. Giles TD, Katz R, Sullivan JM, Wolfson P. Haugland M, Kirlin P et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989; 13: 1240-7.
22. Zannard F, van den Brock SAJ, Bory M. Comparison of treatment with lisinopril versus cnalapril for congestive heart failure. Am J Cardiol 1992; 70: 78-83.
23. ZEBRAH Study Group. A study comparing lisinopril and enalapril in the treatment of moderate-to-severe congestive heart failure. Br J Clin Res 1993; 4: 163-72.
24. Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986; 134: 1129-34.
25. Sovik O. De regionale forskningsetiske komitccr i Norge. Erfaringer og merkesaker gjen-nom mer cnn ti âr. Tidsskr Nor Lgeforen 1997; 117:3109-12.
26. Drummond MF. Resource allocation dé cisions in health care: a role for quality of life assessments? J Chron Dis 1987: 40: 605-16.
27. Nord E. Methods for quality adjustment of life years. Soc Sei Mcd 1992; 34: 559-69.
28. Nord E. Kvalitetsjusterte leveâr - muligheter, begrensninger, alternativer. Tidsskr Nor Laegeforen 1992; 112: 2668-70.
29. Liberate NL, Quaglini S. Barosi G. Cost-effectiveness of Interferon alfa in chronic myelogcnous leukemia. J Clin Oncol 1997; 15: 2673-82.
30. Uhlmann RF, Pearlman RA. Perceived quality of life and preferences for life-sustaining treatment in older adults. Arch Intern Med 1991; 151: 495-7.
31. Dorman PJ, Waddell F, Slattcry J, Dennis M, Sandercock P. Are proxy assessments of health status after stroke with the EuroQol questionnaire feasible, accurate, and unbiased? Stroke 1997; 28: 1883-7.
32. Sneeuw KCA, Aaronsen NK, de Haan RJ. Limburg M. Assessing quality of life after stroke. The value and limitations of proxy ratings. Stroke 1997; 28: 1541-9.
33. Carr-Hill RA, Morris J. Current practice in obtaining the Q in QALYs: a cautionary note. BMJ 1991; 303: 699-701.
34. Nydegger CN. Measuring morale and life satisfaction. I: Fry CL Keith J. red. New methods for old-age research. Strategies for studying diversity. South Hadley, MA: Bergin & Garvey, 1986:213-30.
35. Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia 1997; 38: 154-63.
36. King JT, Sperling MR. Justice AC, O'Connor MJ. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg 1997; 87: 20-8.
37. Nord E, Wisl0ff F, Hjorth M, Westin J. Costutility analysis of melphalan plus prednisone with or without interferon-a2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics 1997: 12: 89-103.
38. Owens DK, Sanders GD. Harris RA, McDonald KM, Heidcnrcich PA, Dembitzer AD et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997; 126: 1-12.
39. Eckman MH. Steerc AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. N Engl J Med 1997; 337: 357-63.
40. Hamel MB, Phillips RS, Davis RB, Desbicns N, Connors AF, Teno JM et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. Ann Intern Med 1997; 127: 195-202.
41. Cronenwett JL. Birkmeyer JD, NackmanGB, Fillinger MF, Bech FR, Zwolak RM et al. Costeffectiveness of carotid endartcrectomy in asymptomatic patients. J Vase Surg 1997; 25: 298-311.